AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment
AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot flash treatment ABCL635 into late-stage studies, with a registrational trial potentially starting around the middle of 2027, Chief Executive C…
AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
AbCellera Biologics Inc. ( ABCL ) Stifel 2026 Healthcare Conference 2026 November 10, 2026 7:00 PM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Conference Call Participants Stephen Willey - Stif…
AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results
AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot-flash treatment ABCL635 into late-stage development next year after a midstage study produced stronger-than-expected efficacy results, CEO Car…
What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call
AbCellera Biologics NASDAQ: ABCL plans to advance its experimental hot flash treatment ABCL635 into late-stage development in 2027 after reporting positive mid-stage results, while shelving further development of a separ…
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.19 per share a year ago.…
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Moderate Buy” from Analysts
AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. One investment an…
● Business WireSep 16, 2026 · 16:05 ETCOMPANY'S OWN WORDS
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.…
BlackRock Inc. Makes New Investment in AbCellera Biologics Inc. $ABCL
BlackRock Inc. purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ: ABCL) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (…
Article counts from the last market-wide feed page, across every symbol we track and not just ABCL · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.